Once-daily dosing in dogs optimizes daptomycin safety. - Wikidata - awgldk - TriplyDB

Once-daily dosing in dogs optimizes daptomycin safety.

Once-daily dosing in dogs optimizes daptomycin safety.

http://www.wikidata.org/entity/Q39537062

about

Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Postgenomic strategies in antibacterial drug discovery.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.Clinical experience with daptomycin in Europe: the first 2.5 years.Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Daptomycin dose-effect relationship against resistant gram-positive organisms In vivo pharmacodynamic activity of daptomycin Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Daptomycin.Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.Daptomycin - a novel antibiotic against Gram-positive pathogens.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.Update on daptomycin: the first approved lipopeptide antibiotic.Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin.Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Normalization of creatine kinase values in a case of rhabdomyolysis during daptomycin treatment The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections.Pre-clinical experience with daptomycin.

P2860

Q26863225-75B8803D-2C24-4324-8C87-49FE2A7E34D2 Q28070326-F496C196-DAB7-4AD7-A916-66D91F462534 Q33239640-4A15EAB5-6764-4284-85A9-3DC6165300FB Q33264579-BA0942D8-6C2D-4F11-A782-858931A57119 Q33429168-4B34E699-B07D-4D74-B553-70AECA4D8202 Q33745572-347D40EF-F97B-482D-AAEC-C74BCE926222 Q33767602-832DEEFB-B5B9-4DF2-BA20-86B9CF57448E Q33834856-CEE0A7B9-B9EE-463B-8B38-C67EA9C6CADA Q34110412-5045CC4D-734A-4A59-A00B-E770889AD233 Q34187667-4A00C7B4-4B0F-48F6-9F86-2E97BF5F049A Q34330270-3DB24DD1-0AA6-4235-BBDC-943D8A0B9059 Q34681219-0D5F1694-4CD7-4989-9FB5-07B37D56871D Q34737743-9B28CDD3-3028-4252-9DA4-D4F485D4585A Q34882125-290C1788-BE81-49F3-8C39-C13F5B93BF9D Q34926950-CCC504AB-5D6D-43D2-B100-EB4CA6CE0C5C Q34936759-FE59EF02-37EC-44E9-AEF5-ED62382ECFA5 Q35005549-248276E8-653A-4BFD-9811-E683F646A472 Q35026595-E71AE57E-DE0B-4440-915E-CD8D6CD6B688 Q35166807-4F455B54-501C-4887-AC40-3B1082BE80ED Q35637066-C66BBF8E-5BC1-4D7C-9FE6-14F34D174E8A Q35701450-B25F90DE-5EA9-4D3B-BBBB-C945C061C9CA Q35771368-9A8F1070-C8B5-4924-BB8F-3CDDEA060BCA Q35848781-84C2967F-E26A-4CA1-9A3A-9CD10DBABDF0 Q35871928-A1742DBE-3775-4C61-938B-2F4D2E1D61E0 Q35912731-46FF511F-D363-4880-B4B2-0AC824841885 Q35925535-C339B45C-6842-47DA-AE2B-FE3F4411C6D2 Q35964560-D5C2980C-CA79-45F6-9F02-F5E2BE53F7FA Q36059234-D4819E9D-7657-4437-AAE1-FB7E25E2CFE9 Q36075986-2BA81B3F-312C-4079-92CB-59A35403032E Q36188333-6471D07E-E696-44D2-A251-A5EC17F062A7 Q36407206-FCC4105E-4D7E-459E-A1E9-26B27307552D Q36521880-DF45B9DD-6D54-4CFF-AB32-C168E34A8BF1 Q36558512-93783706-BEFF-42D8-A691-EDA1AA6A8E47 Q36642946-42A62CE0-4C2A-4B77-A626-D78FFFBF6862 Q36644902-9CB9DDB2-BFC5-45A1-A7FC-4D88BB078CDB Q36718474-79DA4DAF-4887-4E6D-944E-E17DD16D1BC7 Q36777821-C1935080-7AFD-42F1-973C-DDF5F374D8DE Q36865495-B528890D-09A8-49D1-A20F-A31E5282656F Q36937759-73882F8F-772B-419E-8EB6-B39D7E3DF05C Q37284356-F4A59F0A-E95B-4273-ACEA-92B417CB2A31

P2860

Once-daily dosing in dogs optimizes daptomycin safety.

http://www.wikidata.org/entity/Q39537062

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Once-daily dosing in dogs optimizes daptomycin safety.

@en

Once-daily dosing in dogs optimizes daptomycin safety.

@nl

type

label

Once-daily dosing in dogs optimizes daptomycin safety.

@en

Once-daily dosing in dogs optimizes daptomycin safety.

@nl

prefLabel

Once-daily dosing in dogs optimizes daptomycin safety.

@en

Once-daily dosing in dogs optimizes daptomycin safety.

@nl

P1433

Q39537062-51EABE97-8A80-4A49-BB0E-7BAA240DFA40

P1476

Q39537062-382EAF2D-D3D6-45DC-B8B8-36B068C220E3

P2093

Q39537062-003DCFA0-7E6D-4651-B4BF-04FA97F9EC8B

Q39537062-65400520-52EA-4E49-BABE-7293E42A1EBB

Q39537062-853B550B-4508-4FCD-B149-E157CE5A2472

Q39537062-8CC5626D-3012-405E-B1EA-5D26BD101650

Q39537062-96198126-6D9B-4030-B19F-D856CBCBFD11

Q39537062-EF938597-5B13-4218-A410-28AF4D0D2700

P2860

Q39537062-017D6BDF-8D32-4D62-BF63-91E2CEDCF270

Q39537062-1EDDC342-DC89-487F-9069-5053A282786B

Q39537062-248D744E-B16C-4BA5-8EAD-2C7C7A1FA216

Q39537062-33B08ADD-17DD-4C08-8931-244031B0B9E5

Q39537062-43A320FF-2B5A-4913-BBE9-F5778A3051B2

Q39537062-44E3962D-F004-4AFB-B4F8-584BF43CE457

Q39537062-8716CCC6-7F84-428A-854E-1C453401D8E4

Q39537062-9CDD1079-122A-4C38-B0DB-B1BB39593B3C

Q39537062-F4345230-E472-46C5-B9B3-2C0A31095B6F

Q39537062-FDC209B9-3940-49F9-AFA4-90411A3EC391

P304

Q39537062-D75AD90D-5603-4855-908B-72D4C608E9B8

P31

Q39537062-A0512CC9-601A-4ED8-ACC2-0D2763BE46F9

P356

Q39537062-D4C66769-35F1-49F0-A4B5-4893DA76E0B2

P407

Q39537062-3952B3CC-1403-4C45-951E-97C2F7B91DD1

P433

Q39537062-9C692AAB-E1AE-4678-A2BC-5D6D326C76EC

P478

Q39537062-2005B8D5-76BA-4FBA-9E19-E4CDD1CE62B4

P577

Q39537062-11816D52-51CD-4094-A5B5-58ABCBC3D672

P698

Q39537062-03A636DD-385D-4EC2-8474-0ED0D832410E

P932

Q39537062-0E97E8F3-C414-4965-BE03-F86953BBC73B

P356

AAC.44.11.2948-2953.2000

P1433

Antimicrobial Agents and Chemotherapy

P1476

Once-daily dosing in dogs optimizes daptomycin safety.

@en

P2093

C L Berman

http://www.w3.org/2001/XMLSchema#string

F B Oleson

http://www.w3.org/2001/XMLSchema#string

F P Tally

http://www.w3.org/2001/XMLSchema#string

J B Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

J J Lai

http://www.w3.org/2001/XMLSchema#string

K S Regan

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

Destruction and regeneration of skeletal muscle after treatment with a local anaesthetic, bupivacaine (Marcaine)

Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Muscle function after exercise-induced muscle damage and rapid adaptation.

Effect of protein binding of daptomycin on MIC and antibacterial activity.

Creatine kinase in serum: 1. Determination of optimum reaction conditions.

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Daptomycin: a novel agent for Gram-positive infections.

P304

2948-2953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.44.11.2948-2953.2000

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2000-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11036005

http://www.w3.org/2001/XMLSchema#string

P932

101585

http://www.w3.org/2001/XMLSchema#string